Postoperative Analgesic Effects of Using Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block

NCT ID: NCT02544893

Last Updated: 2016-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

93 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

we aimed postoperative analgesic effects of using bupivacaine alone or added dexmedetomidine for ultrasound guided thoracic paravertebral block in thoracotomy

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

paravertebral block is commonly used in the treatment for acute and chronic pain.The duration of paravertebral block could theoretically be prolonged with neurolytic agents. Dexmedetomidine ,an alfa-2 adrenoreceptor agonist, is being used and adjuvant capable of prolonging duration of sensory and motor block on nerve blocks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bupivacaine

0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block

Group Type ACTIVE_COMPARATOR

bupivacaine

Intervention Type DRUG

21 ml 0.5 %bupivacaine is applied paravertebral space

dexmedetomidine

100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block

Group Type ACTIVE_COMPARATOR

dexmedetomidin

Intervention Type DRUG

1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space

serum phsyologic

0,9% 21 ml serum physiologic

Group Type ACTIVE_COMPARATOR

serum physiologic

Intervention Type DRUG

21 ml serum physiologic is applied paravertebral space

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bupivacaine

21 ml 0.5 %bupivacaine is applied paravertebral space

Intervention Type DRUG

dexmedetomidin

1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space

Intervention Type DRUG

serum physiologic

21 ml serum physiologic is applied paravertebral space

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

marcaine precedex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA 1-2
* 18-65 aged
* patient undergoing thoracotomy

Exclusion Criteria

* chronic opioid consumption
* bupivacaine and dexmedetomidine allergies
* coagulopathy
* infection at the needle insertion side
* chronic liver and kidney disease
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

TC Erciyes University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Esra Nur Ünalan

resident

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

esra n ünalan, resident

Role: PRINCIPAL_INVESTIGATOR

TC Erciyes University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Erciyes University Medicine Faculty

Kayseri, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014/649

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.